샘플 요청 목록

 카트 문의
시장보고서
상품코드
2015466

톡소플라스마증 검사 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

Toxoplasmosis Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 188 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 7,353,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 8,495 금액 안내 화살표 ￦ 12,505,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,600 금액 안내 화살표 ￦ 15,604,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전 세계 의료시스템이 조기 진단과 감염성 질환 관리에 집중하고 있는 가운데, 글로벌 톡소플라즈마증 검사 시장은 괄목할 만한 성장세를 보이고 있습니다. 기생충 톡소플라즈마 곤디(Toxoplasma gondii)에 의한 감염성 질환인 톡소플라즈마증은 특히 임산부나 면역력이 저하된 사람들에게 여전히 심각한 공중보건 문제로 대두되고 있습니다. 신속하고 정확한 검출에 대한 요구가 높아지면서 고급 진단 솔루션의 도입이 증가하고 있습니다. 이 시장은 2026년에 24억 달러에 달하며, 2033년까지 35억 달러로 성장할 것으로 예측되고 있으며, 예측 기간 중 CAGR은 5.50%에 달할 전망입니다.

시장 인사이트

톡소플라즈마증 검사 시장은 혈청학적 검사, 분자진단, 영상 진단 기술 등 다양한 진단 기술의 등장으로 진화하고 있습니다. 혈청학적 검사는 저렴한 가격과 접근성 때문에 여전히 주류이지만, 중합효소연쇄반응(PCR)과 같은 분자 진단법은 정확성과 신뢰성으로 인해 점점 더 선호되고 있습니다.

인수공통전염병의 부담 증가와 특히 산전관리의 정기적인 검진 프로그램 확대가 시장 성장에 기여하고 있습니다. 또한 검사실 자동화 및 디지털 진단 플랫폼의 발전으로 검사 효율성이 향상되고 결과 보고 시간이 단축되어 진단의 유효성과 확장성이 향상되고 있습니다.

시장 촉진요인

시장 성장을 이끄는 주요 요인 중 하나는 전 세계에서 톡소플라즈마증 감염률이 증가하고 있다는 점입니다. 이 감염병은 오염된 음식이나 물, 감염된 동물과의 접촉을 통해 전파될 수 있으며, 선진국과 개발도상국 모두에서 광범위한 위험에 노출되어 있습니다.

조기 발견의 중요성에 대한 인식이 높아진 것도 또 다른 주요 성장 요인입니다. 조기 진단은 심각한 합병증, 특히 장기적으로 건강에 영향을 미칠 수 있는 선천성 감염을 예방하는 데 필수적입니다.

진단 툴의 기술 발전도 시장 확대를 더욱 가속화하고 있습니다. 고감도, 고특이성의 검사법 개발과 더불어 검사실 자동화가 진행되면서 진단의 정확성과 접근성이 향상되고 있습니다.

또한 고령자 및 면역 결핍 환자의 증가에 따라 신뢰할 수 있는 검사 솔루션에 대한 수요가 증가하고 있습니다. 이러한 취약한 그룹은 정기적인 모니터링이 필요하며, 이는 시장 성장을 더욱 촉진하고 있습니다.

비즈니스 기회

톡소플라즈마증 검사 시장은 시장 진입 기업에게 큰 성장 기회를 제공하고 있습니다. 아시아태평양과 라틴아메리카의 신흥 경제국들은 의료 인프라 개선과 의료 서비스 투자 확대로 인해 주요 성장 지역이 될 것으로 예상됩니다.

신속하고 정확한 결과를 제공하는 현장 검사 솔루션에 대한 수요가 증가하고 있습니다. 이러한 기술은 센트럴 랩에 대한 접근이 제한적일 수 있는 원격지나 자원이 부족한 환경에서 특히 유용합니다.

또한 인공지능과 데이터 분석과 같은 첨단 기술을 진단 플랫폼에 통합함으로써 새로운 혁신의 길이 열리고 있습니다. 이러한 툴은 진단 정확도 향상, 워크플로우 효율화, 그리고 임상적 판단에 도움을 줄 수 있습니다.

전략적 제휴, 신제품 출시, 인수합병도 시장 진입 기업이 입지를 강화하고 제품 라인업을 확장할 수 있는 기회를 창출하고 있습니다. 연구개발에 대한 지속적인 투자가 시장에서의 혁신과 경쟁력을 촉진할 것으로 예상됩니다.

지역별 분석

북미는 첨단화된 의료 시스템, 높은 인지도, 혁신적인 진단 기술의 적극적인 도입에 힘입어 톡소플라즈마증 검사 시장에서 선도적인 위치를 차지하고 있습니다. 주요 산업 플레이어의 존재는 이 지역의 우위를 더욱 공고히 하고 있습니다.

유럽은 정부 주도의 노력과 임산부 및 신생아 건강에 대한 관심이 높아지면서 시장 점유율이 높은 지역입니다. 이 지역의 잘 구축된 의료 인프라는 진단 검사의 광범위한 보급을 지원하고 있습니다.

아시아태평양은 예측 기간 중 가장 빠른 성장을 보일 것으로 예상됩니다. 급속한 도시화, 의료비 증가, 감염성 질환에 대한 인식의 증가가 이 지역 시장 확대의 주요 요인으로 작용하고 있습니다.

라틴아메리카와 중동 및 아프리카도 지속적인 의료 접근성 개선과 질병 예방 및 조기 진단에 대한 관심 증가에 힘입어 완만한 성장세를 보이고 있습니다.

주요 기업

글로벌 톡소플라즈마증 검사 시장은 혁신과 전략적 확장에 주력하는 몇몇 유력 기업이 진입하고 있는 것이 특징입니다. 주요 기업은 다음과 같습니다. :

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

이들 조직은 파트너십과 제품 혁신을 통해 첨단 진단 솔루션 개발 및 글로벌 사업 확장에 적극 나서고 있습니다.

세분화

검사 유형별:

  • 혈청학적 검사
  • 염색법
  • 간접 적혈구 응집 반응
  • 직접 응집법
  • ELISA
  • PCR
  • 초음파 검사
  • MRI
  • 생검

표본별:

  • 혈액 검체
  • 양수
  • 뇌척수액

최종사용자별:

  • 병원
  • 진료소
  • 진단검사실

지역별:

  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동 및 아프리카

목차

제1장 개요

제2장 시장 개요

제3장 세계의 톡소플라스마증 검사 시장 전망, 2020-2033년

제4장 북미의 톡소플라스마증 검사 시장 전망, 2020-2033년

제5장 유럽의 톡소플라스마증 검사 시장 전망, 2020-2033년

제6장 아시아태평양의 톡소플라스마증 검사 시장 전망, 2020-2033년

제7장 라틴아메리카의 톡소플라스마증 검사 시장 전망, 2020-2033년

제8장 중동 및 아프리카의 톡소플라스마증 검사 시장 전망, 2020-2033년

제9장 경쟁 구도

제10장 부록

KSA

The global toxoplasmosis testing market is gaining notable momentum as healthcare systems worldwide intensify their focus on early diagnosis and infectious disease management. Toxoplasmosis, an infection caused by the parasite Toxoplasma gondii, remains a significant public health concern, particularly among pregnant women and individuals with weakened immune systems. The need for timely and accurate detection is driving the adoption of advanced diagnostic solutions. The market is projected to reach USD 2.4 billion in 2026 and is anticipated to grow to USD 3.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.50% during the forecast period.

Market Insights

The toxoplasmosis testing market is evolving with a wide array of diagnostic technologies, including serological assays, molecular diagnostics, and imaging techniques. Serological testing continues to dominate due to its affordability and accessibility, while molecular methods such as polymerase chain reaction (PCR) are increasingly preferred for their precision and reliability.

The growing burden of zoonotic diseases and the expansion of routine screening programs, particularly in prenatal care, are contributing to market growth. Additionally, advancements in laboratory automation and digital diagnostic platforms are enhancing testing efficiency and reducing turnaround times, making diagnostics more effective and scalable.

Market Drivers

A key factor driving market growth is the rising global incidence of toxoplasmosis infections. The infection can spread through contaminated food, water, and exposure to infected animals, making it a widespread risk across both developed and developing regions.

Increasing awareness regarding the importance of early detection is another major growth driver. Early diagnosis is essential in preventing severe complications, especially congenital infections that can have long-term health implications.

Technological progress in diagnostic tools is further accelerating market expansion. The development of highly sensitive and specific testing methods, along with automation in laboratories, is improving diagnostic accuracy and accessibility.

In addition, the growing population of elderly individuals and immunocompromised patients is increasing the demand for reliable testing solutions. These vulnerable groups require regular monitoring, further supporting the growth of the market.

Business Opportunity

The toxoplasmosis testing market offers substantial opportunities for industry participants. Emerging economies in Asia Pacific and Latin America are expected to be key growth areas due to improving healthcare infrastructure and rising investments in healthcare services.

There is a growing demand for point-of-care testing solutions that deliver rapid and accurate results. These technologies are particularly valuable in remote and resource-limited settings, where access to centralized laboratories may be limited.

Moreover, the integration of advanced technologies such as artificial intelligence and data analytics into diagnostic platforms is opening new avenues for innovation. These tools can enhance diagnostic accuracy, streamline workflows, and support clinical decision-making.

Strategic collaborations, product launches, and acquisitions are also creating opportunities for market players to strengthen their presence and expand their product offerings. Continuous investment in research and development is expected to drive innovation and competitiveness in the market.

Region Analysis

North America continues to hold a leading position in the toxoplasmosis testing market, supported by advanced healthcare systems, high awareness levels, and strong adoption of innovative diagnostic technologies. The presence of major industry players further reinforces the region's dominance.

Europe represents a significant share of the market, driven by increasing government initiatives and a strong emphasis on maternal and neonatal health. The region's well-established healthcare infrastructure supports widespread adoption of diagnostic testing.

Asia Pacific is projected to witness the fastest growth over the forecast period. Rapid urbanization, rising healthcare expenditure, and increasing awareness about infectious diseases are key factors contributing to market expansion in the region.

Latin America and the Middle East & Africa are also experiencing gradual growth, supported by ongoing improvements in healthcare access and increasing focus on disease prevention and early diagnosis.

Key Players

The global toxoplasmosis testing market is characterized by the presence of several prominent players focused on innovation and strategic expansion. Key companies include:

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

These organizations are actively engaged in developing advanced diagnostic solutions and expanding their global footprint through partnerships and product innovations.

Segmentation

By Test Type:

  • Serological Test
  • Dye Test
  • Indirect Hemagglutination Assay
  • Direct agglutination Assay
  • ELISA
  • PCR
  • Ultrasound
  • MRI
  • Biopsy

By Sample:

  • Blood Sample
  • Amniotic Fluid
  • Cerebrospinal Fluid

By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Toxoplasmosis Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Toxoplasmosis Testing Market Outlook, 2020-2033

  • 3.1. Global Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Serological Test
    • 3.1.2. Dye Test
    • 3.1.3. Indirect Hemagglutination Assay
    • 3.1.4. Direct agglutination Assay
    • 3.1.5. ELISA
    • 3.1.6. PCR
    • 3.1.7. Ultrasound
    • 3.1.8. MRI
    • 3.1.9. Biopsy
  • 3.2. Global Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 3.2.1. Blood Sample
    • 3.2.2. ABniotic Fluid
    • 3.2.3. Cerebrospinal Fluid
  • 3.3. Global Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals
    • 3.3.2. Clinics
    • 3.3.3. Diagnostic Laboratories
  • 3.4. Global Toxoplasmosis Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 4.1. North America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Serological Test
    • 4.1.2. Dye Test
    • 4.1.3. Indirect Hemagglutination Assay
    • 4.1.4. Direct agglutination Assay
    • 4.1.5. ELISA
    • 4.1.6. PCR
    • 4.1.7. Ultrasound
    • 4.1.8. MRI
    • 4.1.9. Biopsy
  • 4.2. North America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 4.2.1. Blood Sample
    • 4.2.2. ABniotic Fluid
    • 4.2.3. Cerebrospinal Fluid
  • 4.3. North America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Diagnostic Laboratories
  • 4.4. North America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.3. U.S. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.6. Canada Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Toxoplasmosis Testing Market Outlook, 2020-2033

  • 5.1. Europe Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Serological Test
    • 5.1.2. Dye Test
    • 5.1.3. Indirect Hemagglutination Assay
    • 5.1.4. Direct agglutination Assay
    • 5.1.5. ELISA
    • 5.1.6. PCR
    • 5.1.7. Ultrasound
    • 5.1.8. MRI
    • 5.1.9. Biopsy
  • 5.2. Europe Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 5.2.1. Blood Sample
    • 5.2.2. ABniotic Fluid
    • 5.2.3. Cerebrospinal Fluid
  • 5.3. Europe Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Diagnostic Laboratories
  • 5.4. Europe Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.3. Germany Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.6. Italy Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.9. France Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.12. U.K. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.15. Spain Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.18. Russia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.21. Rest of Europe Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Toxoplasmosis Testing Market Outlook, 2020-2033

  • 6.1. Asia Pacific Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Serological Test
    • 6.1.2. Dye Test
    • 6.1.3. Indirect Hemagglutination Assay
    • 6.1.4. Direct agglutination Assay
    • 6.1.5. ELISA
    • 6.1.6. PCR
    • 6.1.7. Ultrasound
    • 6.1.8. MRI
    • 6.1.9. Biopsy
  • 6.2. Asia Pacific Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 6.2.1. Blood Sample
    • 6.2.2. ABniotic Fluid
    • 6.2.3. Cerebrospinal Fluid
  • 6.3. Asia Pacific Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Diagnostic Laboratories
  • 6.4. Asia Pacific Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.3. China Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.6. Japan Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.9. South Korea Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.12. India Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.15. Southeast Asia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.18. Rest of SAO Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 7.1. Latin America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Serological Test
    • 7.1.2. Dye Test
    • 7.1.3. Indirect Hemagglutination Assay
    • 7.1.4. Direct agglutination Assay
    • 7.1.5. ELISA
    • 7.1.6. PCR
    • 7.1.7. Ultrasound
    • 7.1.8. MRI
    • 7.1.9. Biopsy
  • 7.2. Latin America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 7.2.1. Blood Sample
    • 7.2.2. ABniotic Fluid
    • 7.2.3. Cerebrospinal Fluid
  • 7.3. Latin America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Diagnostic Laboratories
  • 7.4. Latin America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.3. Brazil Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.6. Mexico Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.9. Argentina Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.12. Rest of LATAM Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Toxoplasmosis Testing Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Serological Test
    • 8.1.2. Dye Test
    • 8.1.3. Indirect Hemagglutination Assay
    • 8.1.4. Direct agglutination Assay
    • 8.1.5. ELISA
    • 8.1.6. PCR
    • 8.1.7. Ultrasound
    • 8.1.8. MRI
    • 8.1.9. Biopsy
  • 8.2. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 8.2.1. Blood Sample
    • 8.2.2. ABniotic Fluid
    • 8.2.3. Cerebrospinal Fluid
  • 8.3. Middle East & Africa Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Diagnostic Laboratories
  • 8.4. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.3. GCC Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.6. South Africa Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.9. Egypt Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.12. Nigeria Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.15. Rest of Middle East Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Bio-Rad Laboratories Inc.
    • 9.4.3. Affymetrix Inc.
    • 9.4.4. Beckman Coulter Inc.
    • 9.4.5. Biotest
    • 9.4.6. Cepheid Inc.
    • 9.4.7. GenBio
    • 9.4.8. Danaher Corporation
    • 9.4.9. Thermo Fisher Scientific

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기